Cyxone AB (FRA:4CX) Additional Paid-In Capital : €21.82 Mil(As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Cyxone AB Additional Paid-In Capital?

Cyxone AB's quarterly additional paid-in capital increased from Dec. 2023 (€21.71 Mil) to Mar. 2024 (€21.76 Mil) and increased from Mar. 2024 (€21.76 Mil) to Jun. 2024 (€21.82 Mil).

Cyxone AB's annual additional paid-in capital increased from Dec. 2021 (€18.02 Mil) to Dec. 2022 (€21.15 Mil) and increased from Dec. 2022 (€21.15 Mil) to Dec. 2023 (€21.71 Mil).

Cyxone AB Additional Paid-In Capital Historical Data

The historical data trend for Cyxone AB's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyxone AB Additional Paid-In Capital Chart

Cyxone AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

11.89

16.55

18.02

21.15

21.71

Cyxone AB Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Additional Paid-In Capital	Get a 7-Day Free Trial															19.93	19.66	21.71	21.76	21.82

Cyxone AB Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Cyxone AB Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Cyxone AB's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyxone AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyxone AB (FRA:4CX) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Hyllie Boulevard 34, Malmo, SWE, 215 32

Website

https://www.cyxone.com

Cyxone AB is a clinical biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The product candidates of the company include T20K and Rabeximod.

Cyxone AB Headlines

No Headlines